



PTO/A-820 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Information Disclosure Statement - PTO 1449 (Modified)
Sheet 1 of 1

37 CFR 1.501
INFORMATION DISCLOSURE CITATION
IN A PATENT
(use as many sheets as necessary)

Docket Number (Optional) 57294-021	Application Number 10/808,008
Applicant Roger K. Cady	
Filing Date 03/24/2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initial	Ref.	Document Number								Date	Name	Class	Subclass	Filing Date If Appropriate
CMK	AA	6	2	8	0	7	6	3		08/28/2001	Midha et al	424	448	05/10/1999
CMK	AB	6	3	1	2	7	1	6		11/06/2001	Midha et al	424	448	05/02/2000

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref.	Document Number	Issue Date	Country	International Class	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initial	REF.	DOCUMENT
CMK	CA	DUGGAN ET AL., "INHIBITION OF RELEASE OF NEUROTRANSMITTERS FROM RAT DORSAL ROOT GANGLIA BY A NOVEL CONJUGATE OF A CLOSTRIDIUM BOTULINUM TOXIN A ENDOPEPTIDASE FRAGMENT AND ERYTHRINA CRISTAGALLI LECTIN", THE JOURNAL OF BIOLOGICAL CHEMISTRY, VOL 227, No. 38, SEPT. 20, 2002, PP 34846 - 34852
CMK	CB	BOTOX (BOTULINUM TOXIN TYPE A) PURIFIED NEUROTOXIN COMPLEX (PRODUCT INFORMATION)

EXAMINER 	DATE CONSIDERED 1/8/05
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Burden Hour Statement: This form is estimated to take 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.